Merck Cozaar Approval Nod For Nephropathy Gets Boost From Avapro Data

An advisory committee recommendation for Merck's Cozaar in the treatment of nephropathy in type 2 diabetes patients reflects supportive evidence from Bristol-Myers Squibb/Sanofi's Avapro data.